Status:
COMPLETED
Copeptin in COVID-19
Lead Sponsor:
Al-Azhar University
Conditions:
COVID-19
Eligibility:
All Genders
18+ years
Brief Summary
This study aimed to investigate the change in serum level of copeptin, a neuroendocrine biomarker, in differentiation between mild-moderate and severe COVID-19 cases on admission time and to find its ...
Detailed Description
This prospective study enrolled 160 individuals with confirmed COVID-19 infection using PCR. They were recruited from Al-Zahraa Hospital, Faculty of Medicine (Girls), Al-Azhar University, Cairo, Egypt...
Eligibility Criteria
Inclusion
- Adult patients \> 18 years with the positive result of real-time reverse transcriptase-polymerase chain reaction assay (RT-PCR) for SARS-CoV-2 RNA.
- Severity stratification is based on the guidance of the Egyptian MOH protocol.
Exclusion
- Pregnant COVID-19 patients. COVID-19 patients with morbid obesity, malignancy, autoimmune diseases and those who received immunomodulators or began COVID-19 treatment protocol.
- Also, patients with a history of recurrent COVID-19 will be excluded.
Key Trial Info
Start Date :
June 20 2021
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
September 10 2021
Estimated Enrollment :
160 Patients enrolled
Trial Details
Trial ID
NCT05249751
Start Date
June 20 2021
End Date
September 10 2021
Last Update
February 22 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Al-Zahraa Hospital, Al-Azhar University, Cairo, Egypt
Cairo, Egypt, 11311